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associated with excess mortality in the
243 patients included in the analysis,
and the measured effect of ACSSuT
was achieved by the inclusion of the
nalidixic acid–resistant strains in this
group. However, all deaths associated
with nalidixic acid–resistant strains
occurred in the 40 patients with R-
type ACSSuTNx (being DT104s),
whereas none of the 43 patients infect-
ed with non-ACSSuT strains resistant
to nalidixic acid died. This finding
may be related to small numbers in
these subanalyses. However, because
25 of the patients with R-type
ACSSuTNx were part of an outbreak,
they may have had an average higher
exposure dose, which may have con-
tributed to some deaths (3). In addi-
tion, an interaction between different
resistance traits in Salmonella may
exist, which may lead to more deaths
and disease, or DT104 may be some-
what more virulent than most other S.
Typhimurium subtypes.
The database that we used for our
analysis was updated in May 2002.
We have now identified 13 deaths in
342 patients infected with strains
resistant to ACSSuT (but Nx suscepti-
ble), which corresponds to a relative
mortality rate of 4.18 (95% confi-
dence interval [CI]) 2.18 to 8.02)
compared with a matched sample of
the general population. Of 1,432
patients infected with pansusceptible
strains, 43 patients died (relative mor-
tality rate 2.64; 95% CI 1.88 to 3.70).
In other words, the mortality rate in
patients infected with strains resistant
to ACSSuT (Nx susceptible) was 1.6
times higher than in patients with pan-
susceptible strains (p value for homo-
geneity 0.22). These estimates were
not adjusted for coexisting conditions
as were the estimates in the paper (6). 
We agree with Dahl that particular
problems are associated with
quinolone resistance in zoonotic sal-
monellae and that fluoroquinolones
may have reduced efficacy to treat
patients infected with Salmonella
strains that are nalidixic acid
(quinolone) resistant (7). We therefore
encourage initiatives to preserve the
efficacy of fluoroquinolones, includ-
ing a limitation of their use in agricul-
ture. Whether infection with S.
Typhimurium R-type ACSSuT, with
no additional resistance, is associated
with higher disease or death rates than
pansusceptible  S. Typhimurium
remains unclear. Although the differ-
ence was not significant (p=0.22), our
recent estimates suggest that the death
rate is approximately 60% higher in
patients infected with such strains.
This view is corroborated by recent
studies from the United States, which
suggest that S. Typhimurium R-type
ACSSuT is associated with an
increased risk for blood stream infec-
tion (8) and that resistance in nonty-
phoid  Salmonella is associated with
an increased risk for admission to hos-
pital (9).
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To the Editor: Epidemic meningi-
tis associated with serogroup A
Neisseria meningitidis is a devastat-
ing disease in the absence of vaccina-
tion (1). Without treatment, the case-
fatality rate is high, approaching
100%. In Africa, such epidemics
occur regularly (1) within a well-lim-
ited geographic zone, the so-called1352 Emerging Infectious Diseases • Vol. 9, No. 10, October 2003
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African meningitis belt (2). In the
countries within the meningitis belt,
the illness is endemic and sporadic:
numerous cases of meningococcal
meningitis are reported each year dur-
ing the dry season, and every 6–12
years a large outbreak occurs.
Serogroup A N. meningitidis also
causes sporadic cases of meningitis
outside the meningitis belt, account-
ing for 10% to 30% of cases with
identified causes (1,3). Outbreaks
may also occur outside of the belt, but
they do not exhibit the same epidemi-
ologic aspects. We report an epidemic
of meningococcal meningitis in the
South-West Province of Cameroon
(~500 km south of the African menin-
gitis belt and 350 km east of Yaoundé,
the country’s capital), involving 61
cases and 13 (21%) deaths.
Clinical and epidemiologic
information was collected from
medical records at Bechati Health
Centre and Fontem Missionary
Hospital, the only two care centers in
the epidemic area. Acase was defined
as sudden fever >38°C and neck
stiffness if the patient was >12 months
of age, or bulging fontanelle if the
patient was <12 months of age. Other
symptoms of meningitis, such as
nausea, vomiting, irritability,
confusion, and lethargy to the point of
coma, were observed in several
patients. An epidemic threshold of 15
cases reported in a 2-week period in a
population of >100,000 has the
specificity and probability to predict a
meningococcal epidemic within the
meningitis belt (1). In the Bechati area
(10,326 inhabitants), nine fatal cases
occurred during the first week (March
5–12, 2000), for an attack rate of 87
per 100,000, a figure that local health
authorities considered as epidemic.
The outbreak extended from
March 6 to April 6, 2000, and peaked
March 21–22 (10 cases in 48 hours),
in the area of Bechati (5°40′ north of
the equator, 300 km2). The first case-
patient was retrospectively identified
as a 9-month-old child from Bechati,
treated for meningitis at Fontem
Missionary Hospital on February 25.
This child was shown to have a gram-
negative  Diplococcus infection by
microscopic analysis of a cere-
brospinal fluid (CSF) sample.
(Fontem is a rural city, 15 km from
Bechati, by a poor-quality railroad
track.) The epidemic began on March
5 in Bechati and spread to seven other
villages. The last case was recorded
on April 6. After the index case, 6
cases occurred in week 1; 16 cases in
weeks 2, 3, and 4; and 6 cases in week
5. A total of 61 cases were registered
in the Bechati Health District (33
male and 28 female patients), with a
mean age of 22 years (range 9 months
to 70 years) and an attack rate of 591
per 100,000 (61/10,326). 
The first patient was cured by
appropriate treatment with thi-
amphenicol at Fontem Missionary
Hospital. The next nine case-patients
in these remote villages all died,
either without treatment or despite
traditional treatment. As this
meningococcal epidemic was the first
of its kind in this area, introducing an
efficient response took some time.
The public health authorities intro-
duced chloramphenicol treatment on
March 13; subsequently, four more
deaths occurred, including two
untreated patients, among the next 51
case-patients. The death rate was
100% in week 1 (6/6), 31.3% in week
2 (5/16), 0% in week 3, 12.5% in
week 4 (2/16), and 0% in week 5.
Deaths were more frequent in patients
>20 years of age (12/34; 35%) than in
younger patients (1/27; 4%, p<0.01),
and deaths were highest in 20- to 29-
year-old patients (8/17; 47%). These
findings suggest that the adults were
affected earlier than children and
teenagers. Two (4%) of the 50 patients
treated with chloramphenicol died,
whereas all 11 (100%) untreated
patients died. 
Nine of the 61 patients underwent
some sort of CSF analysis. One had a
positive direct microscopic examina-
tion. Four of the eight CSF samples
taken in the field tested positive for
meningococcus Ain the rapid aggluti-
nation test; from one of these samples,
serogroup A N. meningitidis was iso-
lated. Thus, we considered that the
epidemic was due to meningococcus
A. The strain isolated was susceptible
to major antibiotics, resistant to
trimethoprim/sulfamethoxazole, and
belonged to the epidemic clone
A:4:P1.9 (sequence type ST-7), which
was circulating simultaneously in
north Cameroon and south Chad. The
third pandemic caused by this strain
began in China in 1993, causing large
epidemics in Mongolia in 1994 and
Moscow in 1996 (4). This sequence
type seemed to emerge in Africa since
1995 (5), and researchers hypothe-
sized that severe epidemics attributa-
ble to this ST-7 clone occurred in
Cameroon and Niger, since such
strains were circulating in the popula-
tion and this ST-7 clone was responsi-
ble for severe outbreaks in Chad
(1998) and Sudan (1999) (5). After
meningococcus A was identified on
March 22, the decision was made to
vaccinate the local population.
Polysaccharide A-C meningococcal
vaccines were administered soon after
week 6 in the outbreak area (i.e., after
the epidemic ended).
Bechati is located in an area of
tropical rainforest, with mountains at
an altitude of ~1,000 m and deep
humid valleys in which the villages
are situated. This ecosystem is very
different from the dry Sahelian
ecosystem of the African meningitis
belt. Nonetheless, an outbreak of
serogroup A meningococcal infec-
tions occurred in this zone, so we
investigated the possible causes of
this epidemic. 
The introduction of the strain into
this remote population, probably in
February 2000, was almost certainly
favored by intense commercial
exchanges with surrounding popula-
tions during the coffee harvest period
at the end of the dry season, whenEmerging Infectious Diseases • Vol. 9, No. 10, October 2003 1353
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roads are more navigable than during
the rainy season. The epidemic strain
then spread in the nonimmune popu-
lation, which had no cohort immune
barrier. All age groups had similar
attack rates, in contrast to epidemics
within the meningitis belt, which
essentially affect children; the death
rate in the absence of appropriate
treatment was 100%. We showed that
in 1999 to 2000 in Yaoundé, a large
city situated in the tropical rainforest
at about 600 km south of the meningi-
tis belt, N. meningitidis was isolated
in 13.4% of cases of bacterial menin-
gitis, and most of the strains isolated
belonged to serogroup A (3).
Serogroup A and W135 meningococ-
cal meningitis increased in Yaoundé
between 1995 and 2000, possibly
attributable to increases in human
exchanges between the northern
provinces (situated within the menin-
gitis belt) and the central and southern
provinces (6).
Other trigger factors frequently
considered responsible for epidemics
within the African meningitis belt are
drought and the “Harmattan” wind
because all major epidemics start at
the driest period of the dry season and
stop with the first rains. The
Harmattan wind rarely reaches South
Cameroon. Precipitation has been
recorded over a number of years at
Fontem Missionary Hospital. From
1995 to 1999, yearly rainfall averaged
2,300–2,500 mm, with only 0–50 mm
from November to March. In the past
5 years, an average of no more than
two consecutive months have been
without rain, whereas almost four
consecutive months without rain
(December to the end of March)
occurred just before the epidemic.
Thus, this outbreak appeared to
result from several factors: 1) a
virulent serogroup A strain belonging
to ST-7 that had been responsible for
recent epidemics in surrounding
countries and was circulating in
Cameroon; 2) the expansion of this
strain, favored by the absence of an
immune barrier in the population and
by commercial exchanges; and 3) an
exceptionally dry season. Outbreaks
of meningococcal disease are not
strictly bound to certain ecologic
conditions occurring within the
meningitis belt but may break out
elsewhere. Since the epidemic
reported here, another meningococcus
Aepidemic (~200 cases) has occurred
at a similar equatorial latitude, near
Bamenda (approximately 100 km
north of Fontem), in 2001 (J.
Kamgno, pers. comm.).
Health authorities should be aware
of the possibility of such epidemics,
be ready to alert medical practitioners
and the public about them as they
occur, and ensure that patients receive
proper treatment and vaccines in these
zones.
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To the Editor: Infection by West
Nile virus (WNV) was first recog-
nized in the Western Hemisphere in
1999 in New York (1). Subsequently,
this mosquito-borne flavivirus has
spread westward and has emerged as
an important cause of infectious
meningoencephalitis in the United
States (2). In September 2002, during
a WNV epidemic in Michigan (2), a
38-year-old woman with common
variable immunodeficiency (CVID)
sought treatment at the University of
Michigan Hospital with acute WNV-
associated meningitis. Although per-
sons with CVID are at increased risk
for enteroviral meningoencephalitis, a
greater susceptibility to arthropod-
borne flavivirus infections has not
been reported.
The patient had a history of recur-
rent sino-pulmonary infections and
gastrointestinal giardiasis and salmo-
nellosis; at 33 years of age, she was
diagnosed with CVID that has been
subsequently treated with intravenous
immunoglobulin (IVIG) every 3
weeks. She was in her usual state of
health until 5 days before admission,
when she noted the abrupt onset of
severe headache, followed by temper-
atures up to 39.4°C, progressive pho-
tophobia, nausea, vomiting, and a